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Mark K. Eskandari, MD,b Milwaukee, Wisc; and Chicago, Ill
Objective: We assessed the incidence and outcomes of graft-related secondary interventions (ie, open conversion or
proximal or distal extensions) after elective thoracic endovascular aortic repair (TEVAR) for aneurysmal disease.
Methods: An institutional review of TEVAR for descending thoracic aortic aneurysms (DTAAs), between 2000 and 2011, was
performed. Only elective TEVAR for DTAA using commercially available endografts was selected. Emergent cases, non-
aneurysmal aortic pathology (ie, transection, pseudoaneurysm, dissection), and cases that used physician-modiﬁed devices
were excluded. The incidence of unplanned graft-related secondary interventions was examined and outcomes were analyzed.
Results: During the study period, 83 patients underwent elective TEVAR for DTAA that met the inclusion criteria.
Subsequent graft-related secondary interventions were required in eight patients (10%). The mean interval to the
secondary intervention was 31.8 months. Endoleak was the most common indication. Patients who required secondary
interventions were signiﬁcantly younger (mean age, 58 ± 12 vs 69 ± 11 years; P < .05). Operative mortality (<30 day) was
zero, with one aneurysm-related late death occurring at 2 years after the secondary intervention. Factors that predisposed
the need for secondary interventions were fusiform morphology of the aneurysm (P[ .05) and extent of graft coverage in
the proximal landing zone <3 cm (P < .05). Size of the aneurysm treated and the type of device used were not signiﬁcant
factors leading to secondary intervention.
Conclusions: Intermediate and long-term results of elective TEVAR for DTAA demonstrate good durability, with accept-
able rates of graft-related secondary interventions. Age, fusiform aneurysm morphology, and extent of proximal landing
zones <3 cm were signiﬁcant factors that led to subsequent secondary interventions. (J Vasc Surg 2013;57:1269-74.)Thoracic endovascular aortic repair (TEVAR) has
shifted the paradigm in the treatment of thoracic aortic
disease in acute and chronic settings and has led to
a number of reports on satisfactory short-term and inter-
mediate results regarding its durability.1-6 The need for
secondary interventions is an important indicator of long-
term success of TEVAR. As such, data regarding the
outcomes of secondary interventions are much needed to
identify signiﬁcant clinical risk factors and mechanisms of
failure and to provide assessment on the current limitation
of the evolving technology. This report analyzes the inci-
dence and outcomes of secondary interventions after elec-
tive TEVAR with commercially available endografts for the
treatment of degenerative thoracic aortic aneurysms at
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An Investigational Review Board–approved retrospec-
tive review of TEVAR for descending thoracic aneurysms
(DTAA) between 2000 and 2011 was performed from
a prospectively maintained database at Northwestern
Memorial Hospital. Elective cases of TEVAR for DTAA
using commercially available endografts were selected.
Cases using surgeon-modiﬁed devices, emergent cases,
and cases treating nonaneurysmal thoracic aortic patholo-
gies were excluded. All TEVAR cases were performed
from the transfemoral approach. Routine revascularization
of the subclavian artery was performed when the proximal
landing zone required zone II coverage for minimum 2-cm
seal length.
Study deﬁnitions. Initial TEVAR success was deﬁned
as complete exclusion of the aneurysm without type I or
type III endoleak veriﬁed by completion aortogram.7
The incidence of unplanned graft-related secondary inter-
ventions, deﬁned as any direct surgical or endovascular
maneuver to prevent continued aneurysm progression (ie,
open conversion, proximal and distal endograft extension,
and embolization), was collected and analyzed. Treatment
of nonarterial complications was not included.
Patients were under a strict follow-up protocol that
required a contrast computed tomography scan at 1, 6,
and 12 months after surgery and then annually thereafter.
Magnetic resonance angiography was used alternatively
when chronic renal insufﬁciency or allergy to iodinated
contrast was detected.1269
Fig 1. Cumulative durability of thoracic endovascular aortic repair
(TEVAR) is shown by Kaplan-Meier curves of secondary
intervention-free survival. IQR, Interquartile range.
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mation, including history of diabetes mellitus, chronic
obstructive pulmonary disease, hypertension, and coronary
artery disease, was collected and assessed. Preoperative
imaging information, including aneurysm morphology
and size, and intraoperative data, including length of seal
zones and the need for adjunct procedures (debranching,
coiling, etc), was also collected and analyzed. Primary
outcomes measured were death, stroke, and spinal cord
ischemia. Access site and graft-related complications, in-
cluding kinking, thrombosis, and infection, were collected
and assessed.
Statistical analysis. Discrete data are given as counts
and percentages. Comparisons of continuous data were
performed by Mann Whitney U tests, and groups of cate-
goric data were compared by c2 tests, as appropriate.
Freedom from secondary open surgical conversion after
TEVAR was estimated by the Kaplan-Meier method and
expressed as percentages. A two-sided P value <.05 was
considered statistically signiﬁcant. All statistical analyses
were performed with SAS 8.02 software (SAS Institute,
Cary, NC).
RESULTS
During the study period, 251 TEVAR cases were per-
formed. Of these, we identiﬁed 83 patients who underwent
elective TEVAR for DTAA meeting the exclusion criteria.
Mean total follow-up for the study group was 26.4 months
(range, 1-123.4 months). All 83 cases were successfully
performed with no immediate open conversions. There
was one (1%) early (<30 days) death, two (2%) strokes,
and one (1%) incidence of spinal cord ischemia. There
were eight operative complications (10%), including four
access site complications (5%), one distal embolism (1%),
and three wound infections (4%) that were related to
open femoral cutdowns.
Secondary interventions were acquired at a continuous
rate throughout the follow-up period. Eight patients (10%)
who underwent elective TEVAR for DTAA required
secondary interventions. The mean interval to secondary
intervention was 31.8 months after the initial procedure
(range, 0.5-71.2 months). Two patients in the secondary
intervention group required open conversion, ﬁve required
secondary TEVAR (three proximal extension, one distal
extension, and one relining), and one required endovascu-
lar coiling only for a type II endoleak. The cumulative rates
of freedom from intervention were 96% at 2 years and 85%
at 5 years (Fig 1).
Five different commercially available devices were used
in the study: the TX2 endograft (Cook Medical, Bloo-
mington, Ind), the TAG and the newer-generation
C-TAG devices (Gore Medical, Flagstaff, Ariz), and the
Talent and the newer-generation Valiant devices (Med-
tronic, Minneapolis, Minn). The types of stent grafts and
the frequency of their use are summarized in Table I. For
all devices, the size (diameter) of the stent graft deployed
was calculated from the largest diameter of the proximal
or distal neck with addition of an oversizing factor of20%. A proximal and distal landing zone requirement of
2 cm per universal device instructions for use was adhered
to in each of the cases. When a comparison of device type
used was made between the cohort requiring secondary
intervention and the no reintervention group, the type of
device was not a signiﬁcant factor leading to secondary
interventions (P ¼ .54).
Endoleak was the most common indication leading to
secondary interventions. The type of endoleak and subse-
quent method of treatment is summarized in Table II.
Five patients underwent secondary intervention for a type
I endoleak: four for type IA (Fig 2) and one for type IB.
One patient underwent secondary intervention for a type
II endoleak and one for a type III endoleak. One patient
had no detectable endoleak, but aneurysmal progression
continued on surveillance that required reintervention.
To treat these graft-related failures, two patients required
conversion to an open aortic repair (both arch replace-
ments), and ﬁve required secondary TEVAR, comprising
three proximal extensions, one distal extension, and one
relining for type III endoleak. In conjunction to the
TEVAR, two patients required arch debranching (one
carotid-to-carotid bypass and one carotid-to-subclavian
bypass). One patient required just an endovascular coiling
of a type II endoleak.
Patient demographics and clinical comorbidities were
compared between the secondary intervention cohort and
the no reintervention cohort (Table III). Patients who
required secondary interventions were signiﬁcantly youn-
ger than the patients who required no reinterventions
(mean age, 58 6 12 vs 69 6 11 years; P < .05). Patient
gender and medical comorbidities, including coronary
artery disease, chronic obstructive pulmonary disease, dia-
betes mellitus, and hypertension, were not signiﬁcantly
different between the two groups. Any history of aortic
surgeries (ie, prior arch reconstruction, abdominal aortic
repairs) was also examined. Patients who underwent
secondary interventions did not have a higher rate of prior
aortic operations compared with the no reintervention
group (P ¼ .7).
Table I. Types of endografts used
Device type
Secondary
interventiona
(n ¼ 8), No. (%)
No reinterventiona
(n ¼ 75), No. (%)
Cook TX2b 0 (0.0) 4 (5)
Gore C-TAGc 0 (0.0) 4 (5)
Gore TAGc 5 (60) 52 (69)
Medtronic Talentd 3 (40) 12 (16)
Medtronic Valiantd 0 (0.0) 3 (4)
aThe P values ¼ .54.
bCook Medical, Bloomington, Ind.
cW.L. Gore & Associates, Flagstaff, Ariz.
dMedtronic, Minneapolis, Minn.
Table II. Indication for secondary intervention and
types of subsequent management
Indication
Secondary
intervention (n ¼ 8), No.
Endoleak
Type IA 4
Type IB 1
Type II 1
Type III 1
Aneurysmal progression,
no detectable endoleak
1
Required treatment
Endovascular 6
Open (arch replacement) 2
Secondary TEVAR 5
Proximal extension 3
Arch debranching 2
Distal extension 1
Relining 1
Coiling only 1
TEVAR, Thoracic endovascular aortic repair.
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and compared between the two groups. The mean diam-
eter of the aneurysm treated between the patients who
underwent secondary intervention compared with patients
with no reinterventions, 6.2 6 0.7 vs 6 6 1.2 cm, respec-
tively, was not signiﬁcantly different (P ¼ .57). All patients
who underwent secondary interventions were initially
treated for fusiform aneurysms. Patients who underwent
TEVAR for the treatment of saccular aneurysms did not
require secondary interventions in this study. This was
signiﬁcantly different (P ¼ .05).
We examined whether the length of proximal coverage
along with the need for coverage of the subclavian artery at
the time of initial TEVAR were signiﬁcant determinants for
subsequent reintervention. Any graft needing zone II
landing for required 2-cm coverage had left subclavian
revascularization with subsequent ligation or embolization.
Five of the eight patients needing secondary interventions
required debranching of the left subclavian artery and coil-
ing or carotid-subclavian transposition for extension of the
proximal landing zone during the initial TEVAR. Twenty-ﬁve patients (33%) in the no reintervention group required
coverage of the left subclavian artery. Although the
frequency of left subclavian coverage was lower in the no
reintervention group, the difference was not statistically
signiﬁcant (P ¼ .13). The proximal seal length was mea-
sured and compared between the two groups. The mean
length of the proximal landing zone was 2.3 6 1.2 cm in
the secondary intervention group vs 3.3 6 1.1 cm in the
no reintervention group. This was signiﬁcantly different
(P ¼ .03).
The complication rates in patients who underwent
secondary interventions were compared with the patients
requiring no reinterventions. The results are summarized
in Table IV. In the secondary intervention group, clinically
relevant perioperative (<30 days) events occurred in three
patients, with one stroke and two access site complications.
Operative mortality (<30 day) was zero as was the inci-
dence of spinal cord injury. All complications occurred
after secondary TEVARs. No unexpected events occurred
in the two patients who underwent open conversion. One
aneurysm-related late death occurred at 1.5 years in
a patient who underwent open aortic arch replacement.
The patient developed an irrecoverable infection of the
prosthetic graft and died after comfort measures were
initiated.
Early perioperative events occurred in 11 patients in the
no reintervention group. The most common operative
complication was access-related in four patients (5%). There
was one (1%) early death, one (1%) stroke, and one (1%)
incidence of spinal cord injury. There was one procedure-
related distal embolism and resultant limb loss. Surgical
site infection from groin cutdown for femoral access
occurred in three patients (4%) in this cohort. Three patients
(4%) in the no reintervention cohort died late (>90 days)
after TEVAR from suspected aneurysm rupture. The cumu-
lative rates of early and late operative complications after
secondary interventions were not statistically different
compared with patients who did not require reintervention
(P ¼ .999).DISCUSSION
The need for secondary interventions is an important
indicator of the durability of endovascular aortic repair.
Existing publications that have reported outcomes after
TEVAR largely consist of mixed elective and emergency
cases for varying thoracic aortic disease, including aortic
dissections and penetrating aortic ulcers.8-12 Our assess-
ment of TEVAR outcomes was restricted to reviewing
data from those patients who were electively treated for
degenerative thoracic aneurysms using off-the-shelf
devices. We believe that limiting the analysis to the partic-
ular aortic pathology that TEVAR was originally designed
to treat (degenerative aneurysms) that are within device
instructions for use, allows for a more accurate evaluation
of the durability and limitations of the technology. Further
restricting the analysis to commercially available endografts
enhances the clarity of this report.
Fig 2. An intraoperative arch aortogram demonstrates a type IA
endoleak (arrows) after thoracic endovascular aortic repair
(TEVAR).
Table III. Demographic, clinical, and morphologic
characteristics of patients requiring secondary
interventions and no reinterventions
Variable a
Secondary
intervention
(n ¼ 8)
No
reintervention
(n ¼ 75) P
Characteristics
Age, years 58 6 12 69 6 11 .0069
Male sex 3 (38) 45 (60) .2725
Coronary artery disease 6 (75) 66 (88) .8024
COPD 3 (38) 37 (49) .7421
Diabetes mellitus 2 (25) 33 (44) .1572
Hypertension 8 (100) 62 (83) .6723
History of prior aortic
surgery
3 (38) 23 (31) .7010
Aneurysm size, cm 6.2 6 0.7 6 6 1.2) .5702
Morphology .0522
Fusiform 8 (100.0) 49 (65)
Saccular 0 (0.0) 26 (35)
Proximal involves coverage
of the left subclavian artery
5 (63) 25 (33) .1307
Proximal landing zone, cm 2.3 6 1.2 3.3 6 1.1 .0320
COPD, Chronic obstructive pulmonary disease.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
Table IV. Outcomes of secondary intervention vs no
reintervention
Outcomes
Secondary
intervention
(n ¼ 8), No. (%)
No
reintervention
(n ¼ 75), No. (%) P
Early (<30 days)
complications
3 (38) 11 (15) .3623
Death 0 (0) 1 (1) .9999
Stroke 1 (13) 1 (1) .5777
Spinal cord injury 0 (0) 1 (1) .9999
Access site
complications
2 (25) 4 (5) .4844
Distal embolism 0 (0) 1 (1) .9999
Infection 0 (0) 3 (4) .7536
Late (>90 days)
aneurysm-related
death
1 (13) 3 (4) .5023
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niques for Aortic Aneurysm Repair (EUROSTAR) registry
collaborators have the largest study to date, which reviewed
secondary interventions after elective TEVAR cases. Theyreported a 2-year freedom from intervention rate of 83%
in 213 elective TEVAR cases studied.13
In our series of 83 elective patients, we report a 2-year
cumulative durability of 96% and a 5-year durability of
83% for elective TEVAR, with a mean time to intervention
of 32 months (Fig 1). The absolute secondary intervention
rate of 10% is also lower than the 12% reported by the
registry13 but approaches the rates reported with current-
generation endografts in the treatment of abdominal aortic
aneurysms (EVAR).14,15 As reported in other studies, the
type of endograft used was not a signiﬁcant determinant of
TEVAR success13,16,17 and the performance of all currently
available off-the-shelf devices can be concluded to be equal.
The improved rates of secondary interventions reported in
our series may be the result of institutional uniformity in
the approach to TEVAR cases along with selection bias for
cases that have strictly adhered to anatomic standards
required by current commercial endografts.
As with other reports, endoleak was the most common
etiology leading to secondary interventions,8,13,17,18 and
proximal type IA endoleak was the most prevalent type
(Table II). Interestingly, one patient had progression
of the aneurysm sac without a detectable endoleak. Most
endoleaks were managed with endovascular techniques,
with a 25% rate of open conversion in our series. Of those
that required secondary endovascular interventions, arch
debranching was required in one-third of the patients. On
the basis of our ﬁndings, most late TEVAR failures can be
managed with endovascular means. The need for open
debranching or full open conversion rate, however, is not
insigniﬁcant.
Of the patient clinical and demographic risk factors
assessed, younger age was correlated signiﬁcantly with the
need for secondary intervention (Table III). There was
no difference in the prevalence of medical comorbidities
in the patients who underwent secondary interventions.
Younger age as a determinant of TEVAR failure contradicts
the ﬁndings of other reports where older age was correla-
tive. A recent study by Alsac et al18 found that age >80
JOURNAL OF VASCULAR SURGERY
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intervention. Careful analysis of the study revealed that
all of the older patients who developed signiﬁcant endo-
leaks in that study had fusiform aneurysm morphology,
which may be the more important determinant of TEVAR
failure. Fusiform morphology, compared with saccular
morphology where aortic deterioration is localized, is
indicative of a progressive ectatic process that allows diffuse
deterioration of the aortic wall. The eight patients who
underwent secondary intervention in our study also had
fusiform aneurysms, which was signiﬁcant (Table III).
What we are observing in this study may be that younger
age is an indicator for risk accumulation; the younger the
patient, the greater the cumulative risk of progressive aortic
ectasia, subsequent aneurysm progression, and hence,
TEVAR failure. Young age and fusiform morphology,
where a global degenerative process exists, become syner-
gistic determinants of later secondary intervention.
Further analysis of the morphologic characteristics of
aneurysms treated in our study showed that aneurysm size
and a proximal neck requiring debranching for adequate
coverage (involves coverage of the left subclavian) were
not signiﬁcant factors leading to secondary intervention
(Table III). The most signiﬁcant anatomic determinant for
TEVAR success appeared to be the length of the proximal
landing zone<3 cm.Themean length of proximal endograft
seal was 2.3 cm, greater than the indicated 2-cm seal zone
that is universal among the commercially available endo-
grafts used.1,9,19-22 As previously reported,23 to obtain the
required 2-cmproximal neck, debranching of the left subcla-
vian artery and subsequent coverage of the ostium was often
undertaken in our cases (30 of 83 cases, 36%). In compar-
ison, the mean length of proximal seal in the no reinterven-
tion group was 3.3 cm in our study. A number of other
studies have demonstrated that the current IFU of a 2-cm
graft-to-aorta seal zonemay not be enough4,16,18 and should
be extended to 3 cm. Unfortunately, we did not have
complete measurements of the proximal diameter at the
seal zone for analysis and admit that this is a weakness of
this study.
The initial technical success of TEVAR was 100% in our
study. Patients who received a secondary intervention did
not have increased morbidity or mortality compared with
patients who did not undergo a reintervention. The compar-
ative complication rates were not signiﬁcantly different
between the two groups, and the assessment may be limited
by the overall small numbers in the cohort. Access site
complications were the most prevalent in the secondary
intervention group and the no reintervention group
(Table IV).
CONCLUSIONS
Elective endovascular repair of degenerative thoracic
aneurysms using commercially available devices has accept-
able durability and outcomes approaching that of EVAR.
All available off-the-shelf grafts seem to perform equally.
We found that most secondary interventions can be
managed with endovascular techniques and haveacceptable rates of operative complications and mortality.
The need for open conversion and arch debranching,
however, is not insigniﬁcant. The risk of secondary inter-
vention is greatest in young patients with fusiform aneu-
rysms, who require regular surveillance imaging and
follow-up. The length of proximal endograft seal is critical,
and the current standard of 2-cm coverage may not be
adequate, as implied by the data in this study as well as
others. We propose the requirement of a 3-cm seal for
durable outcomes after TEVAR.AUTHOR CONTRIBUTIONS
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